{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-23-000085","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.405702+00:00","generated_at":"2026-06-12T03:48:27.438321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Exagen Q2 revenue $14.1M, record AVISE CTD tests; net loss narrows to $5.0M","bullets":["Revenue $14.1M, up 26% QoQ from $11.2M (Q1 2023) and up from $7.6M (Q2 2022).","Record 37,749 AVISE CTD tests (+8% YoY); trailing 12-month ASP $320.","Gross margin 58.7% (Q2 2023) vs 20.1% (Q2 2022); net loss $5.0M vs $14.7M loss a year ago.","Q3 2023 revenue guidance $10M-$10.5M; cash $31.5M as of June 30, 2023.","Operating expenses $19.1M, down from $21.7M due to December 2022 headcount reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-23-000085","json":"https://secwatch.observer/filing/0001274737-23-000085.json","markdown":"https://secwatch.observer/filing/0001274737-23-000085.md","text":"https://secwatch.observer/filing/0001274737-23-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000085/0001274737-23-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000085/exdx-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:48:27.438321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a94bf5677af7c69044ac8a145b3c2ee8894a33b","claim":"EXAGEN INC. reported quarter ended June 30, 2023 results: revenue $14.1 million. Guidance initiated.","evidence_excerpt":"Second Quarter Highlights: • Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022. • Recognized total revenue of $14.1 million for the second quarter, a 26% increase over the first quarter of 2023. • Achieved gross margin of 54% in the six months ended June 30, 2023. • AVISE® CTD trailing twelve-month","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000085/0001274737-23-000085-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Revenue","value":"$14.1 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4eeba57c17e061765b47e2da9f26bd17a4ea98ac","claim":"EXAGEN INC. reported financial results for six months ended June 30, 2023.","evidence_excerpt":"On August 7, 2023 , the Company reported its financial results for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473723000085/0001274737-23-000085-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}